Daily - Oct 22, 2026 - Show Notes
Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
https://sozointuition.com
SUMMARY
Welcome to the SOZO biotech daily brief. Today, our lead stories cover an FDA accelerated approval for AstraZeneca in primary immunoglobulin A nephropathy, mid-stage clinical trial results from Lumen Bioscience in Clostridioides difficile, and a multi-target miniprotein discovery alliance between Astellas Pharma and AI Proteins. We also follow pipeline progress from Newron Pharmaceuticals and Thiogenesis Therapeutics, alongside new venture backing for Reju Therapeutics. Sources are in the show notes.
CHAPTERS AND SOURCES
00:00 - SOZO Biotech Daily Brief
00:34 - AstraZeneca's Ultomiris Wins FDA Accelerated Approval
Ultomiris received accelerated approval in the US as first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A…:
https://www.astrazeneca.com/media-centre/press-releases/2026/ultomiris-approved-in-us-in-igan.html
01:38 - Lumen Reports Phase 2 RePreve Results for LMN-201
Lumen's LMN-201 shows positive RePreve Phase 2 results in C. difficile 2026-10-22:
https://www.lumen.bio/2026/10/22/lumen-s-lmn-201-shows-positive-re-preve-results-in-c-difficile
02:32 - Astellas and AI Proteins Form Miniprotein Discovery Pact
Astellas Pharma and AI Proteins enter miniprotein discovery collaboration valued at over $400 million 2026-10-21:
https://www.businesswire.com/news/home/20261021073833/en/AI-Proteins-Announces-Research-Collaboration-and-License-Agreement-With-Astellas-Pharma-to-Discover-and-Develop-Novel-Miniprotein-Based-Therapeutics-Valued-at-Over-%24400-Million
03:18 - Newron Completes Phase 3 ENIGMA-TRS 1 Enrollment
Newron completes enrollment of pivotal Phase 3 ENIGMA-TRS 1 study of evenamide 2026-10-22:
https://www.newron.com/news-and-media/regulatory-news/newron-completes-enrollment-pivotal-phase-3-enigma-trs-1-study
03:54 - FDA Clears TTI-0102 IND in Nephropathic Cystinosis
Thiogenesis announces FDA clearance of IND for TTI-0102 in nephropathic cystinosis 2026-10-22:
https://finance.yahoo.com/healthcare/articles/thiogenesis-announces-fda-clearance-ind-090000510.html
04:29 - Nanjing Reju Therapeutics Closes Oversubscribed Series A
Reju Therapeutics completes oversubscribed Series A financing 2026-10-21:
https://www.vcbeathealth.com/article/63807
04:57 - Looking ahead
05:32 - SOZO Intuition